# argenx: Phase 3 study closed enrollment, 173 enrolled (Primary Immune Thrombocytopenia)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | argenx |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia |
| NCT ID | NCT04812925 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Primary Immune Thrombocytopenia |
| Intervention types | biological |
| Target enrollment | 173 |
| Site countries | United States, Argentina, Australia, Bulgaria, Chile, China, Georgia, Greece, Ireland, Italy, Japan, Jordan |
| Posted | 2021-03-24 |
| Planned start | 2021-11-17 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 173 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04812925). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.